CSF levels of core AD biomarkers, Aβ42, T‐tau, and P‐tau, as well AChE activity were measured in aliquots of CSF samples collected before and after 26 weeks of tideglusib treatment (see Table 1 for details). This evidence concerns the gene ACHE and Alzheimer disease.